High Aldosterone-to-Renin Ratio
A high aldosterone-to-renin ratio (ARR) indicates possible primary aldosteronism (PA), a condition where the adrenal glands autonomously produce excess aldosterone independent of renin stimulation, leading to hypertension, cardiovascular damage, and potentially hypokalemia.
What the High ARR Means
An elevated ARR suggests autonomous aldosterone secretion that is not appropriately suppressed by low renin levels. The most commonly used cutoff is ARR >30 (when aldosterone is in ng/dL and plasma renin activity in ng/mL/h), though this varies by laboratory and measurement method 1. The ARR must be interpreted with an absolute aldosterone level of at least 10 ng/dL (280 pmol/L) to be considered positive, as very low renin alone can falsely elevate the ratio 1.
Primary aldosteronism affects approximately 6% of hypertensive patients in primary care and is even more prevalent in resistant hypertension 2. However, only about 2% of at-risk patients are actually tested, representing massive underdiagnosis 2.
Algorithmic Approach to Confirmatory Testing
The need for confirmatory testing depends on your baseline aldosterone level 3:
When Confirmatory Testing is NOT Needed:
- If aldosterone >550 pmol/L (>20 ng/dL) on at least two measurements with suppressed renin: PA is confirmed, proceed directly to subtype evaluation 3
- If aldosterone <240 pmol/L (<9 ng/dL): PA is ruled out, no further testing needed 3
When Confirmatory Testing IS Needed:
If aldosterone is between 240-550 pmol/L (9-20 ng/dL) with elevated ARR, proceed with confirmatory testing 3.
Recommended Confirmatory Tests
The intravenous saline infusion test is the preferred confirmatory test 3. Here's the hierarchy:
First Choice: Saline Infusion Test
- Administer 2L normal saline IV over 4 hours with patient recumbent
- PA confirmed if post-infusion aldosterone >280 pmol/L (>10 ng/dL) 4
- Contraindicated in severe uncontrolled hypertension or heart failure 3
Alternative: Captopril Challenge Test
- Use when saline infusion is contraindicated 3
- Administer 25-50 mg captopril orally after 1 hour sitting/standing
- Measure aldosterone at baseline and 1-2 hours post-dose
- PA likely if aldosterone fails to suppress by >30% 4
Other Options:
- Oral salt loading: >200 mmol sodium/day for 3 days; PA if 24-hour urinary aldosterone >33 nmol/day 4
- Fludrocortisone suppression test: More cumbersome, less commonly used 3
Critical Pitfalls to Avoid
Medication interference is a major source of false results 1:
- Must withdraw for ≥4 weeks before testing: spironolactone, eplerenone, amiloride, triamterene
- Should withdraw if possible: beta-blockers, ACE inhibitors, ARBs, clonidine
- Can continue: non-dihydropyridine calcium channel blockers, alpha-blockers, hydralazine, prazosin
- Ensure normal potassium levels before testing 1
The ARR is inherently variable due to pulsatile aldosterone secretion 3. In surgically confirmed Conn adenomas, 39% had at least one normal aldosterone reading and 31% had one normal ARR on repeat testing 3. This is why 30-50% of positive ARR screens are false positives that suppress on confirmatory testing 3.
Next Steps After Confirmation
Once PA is confirmed, subtype differentiation is essential to determine surgical candidacy 1:
Adrenal CT scan (3mm cuts) to identify adenomas or hyperplasia 4, 1
Adrenal venous sampling (AVS) is the gold standard for lateralization 1, 4, 1:
Treatment Based on Subtype
For unilateral aldosterone production (adenoma or unilateral hyperplasia):
- Laparoscopic adrenalectomy is the treatment of choice 1, 5
- Improves BP in virtually 100% of patients
- Cures hypertension in approximately 50% 1
For bilateral adrenal hyperplasia or non-surgical candidates:
- Mineralocorticoid receptor antagonists are first-line medical therapy 1, 5
- Spironolactone or eplerenone
- Titrate to normalize renin levels and achieve BP control 8
- Both surgical and medical treatment effectively reduce cardiovascular risk and reverse left ventricular hypertrophy 1
The most recent 2025 Endocrine Society guideline 9 acknowledges ongoing debate about whether confirmatory testing adds value beyond a markedly elevated ARR, but current consensus still supports confirmatory testing for intermediate aldosterone values to avoid unnecessary invasive procedures like AVS in false-positive cases.